ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

By L. Rassenti, L. Huynh, Tracey Toy, Liguang Chen, M. Keating, J. Gribben, D. Neuberg, I. Flinn, K. Rai, J. Byrd and 4 more. New England Journal of Medicine, 2004

980 citations recorded by the source corpus.

Subfields: Genetics, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/d78897c591981a81955df31396396f6302cc0770

Citations in the corpus

• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. (2007, neutral): “core, using previously established methods (39).”
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008, neutral): “Median age, y (range) 57 (17-86) — Younger than 60 y 186 (62) 140 (75) 60 to 69 y 73 (24) 56 (77) 70 y or older 41 (14) 21 (51) Male 211 (70) 154 (73) Female 89 (30) 63 (71) Median time from diagnosis, mo (range) 24 (0-155) — Rai stage 0 11 (4) 10 (91) Rai stages I to II 182 (61) 136 (75) Rai stages”